K-645
/ Kallyope
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 26, 2025
A Study of K-645 in the Treatment of Multiple Migraine Attacks
(clinicaltrials.gov)
- P2 | N=134 | Terminated | Sponsor: Kallyope Inc. | Trial completion date: May 2026 ➔ Nov 2025 | Recruiting ➔ Terminated | Trial primary completion date: May 2026 ➔ Nov 2025; Study stopped for futility based on an interim analysis of efficacy.
Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Migraine • Pain
August 20, 2025
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Kallyope Inc. | Active, not recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Migraine • Pain
August 18, 2025
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks
(clinicaltrials.gov)
- P2 | N=120 | Active, not recruiting | Sponsor: Kallyope Inc.
New P2 trial • CNS Disorders • Migraine • Pain
May 16, 2025
A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-645 in Healthy Volunteers
(ANZCTR)
- P1 | N=16 | Completed | Sponsor: Kallyope, Inc. | Recruiting ➔ Completed
Trial completion • CNS Disorders • Migraine • Pain
1 to 4
Of
4
Go to page
1